ConductScience.org, home

Paper36085537

Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.

Volta M. Neurotherapeutics, 2023. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models. Papers, record 36085537. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36085537

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
PubMed
Journal
Neurotherapeutics
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
1.18
iCite
Revised in PubMed
2024-02-04
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Volta MMattiahttps://orcid.org/0000-0002-0300-6796

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
alpha-SynucleinMajor topic
GlucosylceramidaseMajor topic
LysosomesMajor topic
Parkinson DiseaseMajor topic
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Major topic
Animals
Mutation

Source PubMed

Download CSV of topics

References130

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134550621Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.Mov Disord2022https://conductscience.org/library/papers/34550621PubMed
26823561Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.Science1983https://conductscience.org/library/papers/6823561PubMed
315333840Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.Science2004https://conductscience.org/library/papers/15333840PubMed
427859541Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.Ann Neurol2016https://conductscience.org/library/papers/27859541PubMed
517362839Autophagy and neurodegeneration: when the cleaning crew goes on strike.Lancet Neurol2007https://conductscience.org/library/papers/17362839PubMed
69197268Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.Science1997https://conductscience.org/library/papers/9197268PubMed
731039583LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function.Hum Mol Genet2019https://conductscience.org/library/papers/31039583PubMed
821494637Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.PLoS One2011https://conductscience.org/library/papers/21494637PubMed
934340748Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice.Elife2021https://conductscience.org/library/papers/34340748PubMed
1034419621Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.Neurobiol Dis2021https://conductscience.org/library/papers/34419621PubMed
1112941575The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?Lancet Neurol2003https://conductscience.org/library/papers/12941575PubMed
1217101029Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.J Neurochem2007https://conductscience.org/library/papers/17101029PubMed
1331920513Autophagy and LRRK2 in the Aging Brain.Front Neurosci2019https://conductscience.org/library/papers/31920513PubMed
1429704272Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.Mov Disord2018https://conductscience.org/library/papers/29704272PubMed
1524244710Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.PLoS One2013https://conductscience.org/library/papers/24244710PubMed
1619878656Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease.Biochem Biophys Res Commun2009https://conductscience.org/library/papers/19878656PubMed
1727413152G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.J Neurosci2016https://conductscience.org/library/papers/27413152PubMed
1829703245D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.Acta Neuropathol Commun2018https://conductscience.org/library/papers/29703245PubMed
1932034799Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.Mov Disord2020https://conductscience.org/library/papers/32034799PubMed
2017512502Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.Brain Res2007https://conductscience.org/library/papers/17512502PubMed

See all 130 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42707090Mitochondrial resilience: a convergent framework for pathogenesis and neuroprotection in Parkinson's disease.Front Pharmacol2026https://conductscience.org/library/papers/42707090PubMed
41467444Interplay of GBA1 with lysosomal dysfunction and inflammation in Parkinson's disease.Neural Regen Res2026https://conductscience.org/library/papers/41467444PubMed
41383374Mass spectrometry-based proteomics for biomarker discovery in the Drosophila model of Parkinson's disease.Neuroprotection2024https://conductscience.org/library/papers/41383374PubMed
41257354Parkinson's-Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa.Mov Disord2026https://conductscience.org/library/papers/41257354PubMed
40629324Recent advances in targeting LRRK2 for Parkinson's disease treatment.J Transl Med2025https://conductscience.org/library/papers/40629324PubMed
39760821Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.Neurol Sci2025https://conductscience.org/library/papers/39760821PubMed
37017897A New Look at Animal Models of Neurological Disorders.Neurotherapeutics2023https://conductscience.org/library/papers/37017897PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GBA12629PubTator's text mininghttps://conductscience.org/library/genes/2629NCBI Gene
LRRK2120892PubTator's text mininghttps://conductscience.org/library/genes/120892NCBI Gene
SNCA6622PubTator's text mininghttps://conductscience.org/library/genes/6622NCBI Gene
TPCN2219931PubTator's text mininghttps://conductscience.org/library/genes/219931NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36085537

GET https://conductscience.org/api/papers/v1/36085537/references?page=2